市场调查报告书
商品编码
1540855
2024-2032 年按产品和服务、技术、应用、最终用户和地区分類的流式细胞仪市场报告Flow Cytometry Market Report by Product and Service, Technology, Application, End-User, and Region 2024-2032 |
IMARC Group年全球流式细胞仪市场规模达58亿美元。个人化医疗产品的广泛采用、生命科学和生物技术研究活动的扩大以及对学术和研究机构的资助不断增加是推动市场的一些主要因素。
流式细胞仪是一种可以对异质群体中的单一细胞进行详细的多参数分析的技术。该技术使用光来检测和测量细胞或颗粒群的物理和化学特性。每个颗粒悬浮在流体流中并通过电子检测装置。将一束光射到流上,光散射是粒子及其特性的特征。这些模式的强度可用于导出有关每个细胞的物理和化学结构的各种类型的资料。这些资讯在诊断和生物医学研究等广泛应用中都很有价值。它可以每秒快速分析数千个粒子,并同时收集有关单一细胞的多个参数的资料。因此,它是细胞生物学和医学的重要工具。
生命科学和生物技术研究活动的扩展主要推动全球市场。它是细胞生物学、免疫学和肿瘤学研究的重要工具。它广泛用于细胞週期和增殖、凋亡和其他细胞功能的研究。这些研究领域(尤其是发展中国家)的投资不断增加,影响了对这些仪器、试剂和软体的需求。此外,这些方法在疾病检测和监测方面的精确度和效率使其成为个人化医疗的理想选择。随着这种医疗模式的采用率不断上升,它正在显着推动市场的成长。除此之外,学术和研究机构,特别是从事细胞研究的学术和研究机构的资金不断增加,一直是市场的重要推动力。这些资金有助于购买先进的细胞计数技术和新应用的开发,并推动整体市场的成长。此外,人们越来越意识到早期诊断和治疗的好处,加上中产阶级人口的不断增长,正在创造积极的市场前景。
慢性病盛行率增加
癌症、爱滋病毒/爱滋病和其他免疫系统相关疾病等慢性病发病率的上升极大地推动了对流式细胞仪的需求。除此之外,流式细胞仪在几种血液恶性肿瘤的诊断和预后中不可或缺,并且越来越多地用于监测疾病进展和治疗反应。随着全球人口老化和此类疾病的盛行率增加,对快速、准确的诊断和监测工具的需求也在增加。因此,医疗保健产业不断努力提供有效的治疗和改善患者的生活质量,成为流式细胞仪市场的重要动力。
增加临床试验和药物发现的采用
该方法在临床试验和药物发现中的广泛采用是一个重要的市场驱动力。此外,流式细胞仪能够提供有关单一细胞和细胞群的详细信息,使其成为评估药物效果和识别潜在治疗靶点的理想选择。除此之外,製药公司越来越依赖这些方法进行临床前测试和临床试验,以评估新药的安全性和有效性。因此,它对市场产生正面影响。随着製药业的不断扩大和新药候选数量的不断增加,该领域对流式细胞仪的需求大幅加速,推动了市场的整体成长。
持续的技术进步
流式细胞仪产业的主要市场驱动力之一是该领域的持续技术进步。高通量流式细胞仪的出现、提供更好资料分析的软体解决方案的进步以及特定探针和试剂的开发显着提高了流式细胞仪的功效。此外,紧凑、用户友好且价格实惠的系统的引入导致了该技术的民主化,将其用途从研究实验室扩展到临床环境,甚至床边诊断。多色检测和试剂也增加,可以同时检测许多参数,进一步增强了能力。这些进步不仅提供了更有效率、更可靠的结果,而且扩大了潜在应用范围,从而促进了市场的成长。
The global flow cytometry market size reached US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032. The widespread product adoption in personalized medicine, the expansion of research activities in life sciences and biotechnology, and the accelerating funding for academic and research institutes are some of the major factors propelling the market.
Flow cytometry is a technology that allows detailed multi-parameter analysis of individual cells within a heterogeneous population. This technique uses light to detect and measure physical and chemical properties of a population of cells or particles. Each particle is suspended in a stream of fluid and passed through an electronic detection apparatus. A beam of light is directed onto the stream, and the light scatter is characteristic of the particles and their properties. The intensity of these patterns can be used to derive various types of data about the physical and chemical structure of each cell. This information is valuable in a wide range of applications, including diagnostics and biomedical research. It can quickly analyze thousands of particles per second and concurrently gather data about multiple parameters of a single cell. Therefore, it is an essential tool in cell biology and medicine.
The expansion of research activities in life sciences and biotechnology majorly drives the global market. It is a crucial tool in cell biology, immunology, and oncology research. It is extensively used in the study of cell cycle and proliferation, apoptosis, and other cellular functions. The rising investments in these research areas, especially in developing countries, have influenced the demand for these instruments, reagents, and software. In addition, the precision and efficiency of these method in the detection and monitoring of diseases make it ideal for personalized medicine. As this medical model continues to rise in adoption, it is significantly driving the growth of the market. Apart from this, the accelerating funding for academic and research institutes, particularly those engaged in cell-based research, has been a considerable driver for the market. These funds facilitate the purchase of advanced cytometry technologies and the development of new applications, driving the overall market growth. Moreover, the accelerating awareness about the benefits of early diagnosis and therapeutics, coupled with a growing middle-class population is creating a positive market outlook.
Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases such as cancer, HIV/AIDS, and other immune system-related diseases has substantially driven the demand for flow cytometry. Along with this, flow cytometry is indispensable in the diagnosis and prognosis of several hematological malignancies and is increasingly being used in monitoring disease progression and treatment response. As the global population ages and the prevalence of such diseases increases, the need for fast, accurate diagnostic and monitoring tools also grows. Consequently, the healthcare sector's ongoing efforts to provide effective treatments and improve patients' quality of life act as a significant driving force for the flow cytometry market.
Increased Adoption in Clinical Trials and Drug Discovery
The widespread adoption of the method in clinical trials and drug discovery is a significant market driver. In addition, flow cytometry's ability to provide detailed information about individual cells and cellular populations makes it ideal for evaluating drug effects and identifying potential therapeutic targets. Apart from this, pharmaceutical companies are increasingly relying on these methods for preclinical testing and clinical trials to assess the safety and efficacy of new drugs. Therefore, it is positively influencing the market. With the expanding pharmaceutical industry and escalating number of new drug candidates, the demand for flow cytometry in this domain is accelerating substantially, driving the overall growth of the market.
Continuous Technological Advancements
One of the primary market drivers for the flow cytometry industry is the continued technological advancements in this field. The emergence of high-throughput flow cytometry, advancement in software solutions that offer better data analysis, and development of specific probes and reagents have significantly improved the efficacy of flow cytometry. Additionally, the introduction of compact, user-friendly, and affordable systems has led to the democratization of this technology, expanding its use from research labs to clinical settings and even point-of-care diagnostics. There has also been a rise in multicolor assays and reagents which allow simultaneous detection of many parameters, further enhancing the capabilities. These advancements not only provide more efficient and reliable results but also widen the range of potential applications, thereby contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each segment of the global flow cytometry market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product and service, technology, application and end-user.
Instruments
Reagents and Consumables
Accessories
Software
Services
Instruments dominate the market
The report has provided a detailed breakup and analysis of the market based on the product and service. This includes instruments, reagents and consumables, accessories, software, and services. According to the report, instruments represented the largest segment.
In the industry, market drivers for instruments and services are multifaceted. As instruments become more precise, user-friendly, and affordable, they facilitate an expanded range of applications, thus driving demand. In addition, the development of portable and benchtop flow cytometers has made the technology more accessible, boosting the sales of these instruments. Services related to flow cytometry, such as maintenance, training, and data analysis, also experience increased demand driven by the growing usage of this method in various sectors. The complexity of the method data requires specialized software and skilled professionals for analysis, making these services critical. As more businesses and research institutions adopt flow cytometry, they often seek out these services to ensure effective operation and accurate results, further propelling the market for these services.
Cell-Based Flow Cytometry
Bead-Based Flow Cytometry
Cell-based flow cytometry dominates the market
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes cell-based flow cytometry and bead-based flow cytometry. According to the report, cell-based flow cytometry represented the largest segment.
The market for cell-based technology in the industry is driven by the increasing incidence of diseases such as cancer, where it plays a critical role in diagnosis and monitoring. This technology provides valuable information about cellular characteristics and behavior, making it crucial for understanding disease progression and treatment response. In addition, advancements in cell-based research, including stem cell research and cell therapeutics, contribute significantly to the market growth. These fields require in-depth cellular analysis, and flow cytometry is a key tool to meet these needs. In addition, the growing interest in personalized medicine, which requires precise information at the cellular level to develop individualized treatment strategies, is another driving factor. Moreover, the rise of single-cell analysis in genomics and proteomics is boosting the demand for cell-based flow cytometry, given its capability to analyze individual cells within a population.
Oncology
Drug Discovery
Disease Diagnosis
Stem Cell Therapy
Organ Transplantation
Hematology
Others
Oncology dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, hematology, and others. According to the report, oncology represented the largest segment.
The market in the field of oncology is largely driven by the rising global incidence of cancer and the indispensable role of this method in cancer research and patient management. Flow cytometry provides rapid, detailed analysis of cell populations, making it essential for diagnosing various forms of cancer, particularly hematological malignancies. It is also widely used for monitoring disease progression and response to treatment, thereby contributing to the decision-making process in cancer management. In confluence with this, the esclating adoption of personalized medicine in oncology, which requires high-resolution cellular analysis to develop tailored treatment strategies, further propels the demand for flow cytometry. Additionally, advancements in flow cytometry technology, such as the development of multicolor flow cytometry, have significantly enhanced its capabilities in cancer research.
Hospitals and Clinics
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Others
Hospitals and clinics dominate the market
A detailed breakup and analysis of the market based on the end-user have also been provided in the report. This includes hospitals and clinics, academic and research institutes, pharmaceutical and biotechnology companies, and others. According to the report, cell-based hospitals and clinics represented the largest segment.
The market within hospitals and clinics is being driven by the growing prevalence of diseases that require flow cytometry for diagnosis and monitoring, such as cancers and immunological disorders. As the patient load for these conditions grows, so does the need for rapid, accurate diagnostic tools in these healthcare settings. Moreover, technological advancements have resulted in more compact and user-friendly flow cytometers, making it easier for hospitals and clinics to adopt this technology. The rise of personalized medicine also promotes the use of flow cytometry in these settings, as it provides the detailed cellular analysis needed for personalized treatment strategies. In addition, as this method becomes more recognized for its ability to deliver fast and comprehensive results, insurance providers are increasingly covering flow cytometry-based tests, further promoting its adoption in hospitals and clinics.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest flow cytometry market share
The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others); Latin America (Brazil, Mexico, and Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The growth of the flow cytometry industry in North America is driven by a well-established healthcare infrastructure and robust research environment, both of which foster the adoption and development of advanced technologies. Along with this, the high incidence of chronic diseases such as cancer, where this method plays a crucial role in diagnosis and monitoring, also contributes to market growth. Additionally, the presence of leading companies in this region supports the development of innovative technologies and applications. Furthermore, the significant investment in research and development, including biomedical research, clinical trials, and drug discovery processes that extensively use flow cytometry, further fuels market growth. The region's growing interest in personalized medicine, which requires detailed cellular analysis provided by flow cytometry, also contributes to the market demand.
The global flow cytometry market is experiencing significant growth due to the growing investments in research and development to create advanced flow cytometry technologies. This includes the development of new instruments, reagents, software, and methodologies. These advancements aim to enhance the capabilities of flow cytometry, making it more precise, efficient, and user-friendly. Along with this, the escalating number of strategic partnerships with other businesses, research institutions, and healthcare providers is significantly supporting the market. These collaborations often aim to advance research, develop new applications, and broaden the reach of flow cytometry technology. Apart from this, the manufacturers are introducing education and training services, such as workshops, webinars, or online tutorials to help users fully utilize the potential of flow cytometry in their work. Therefore, it is significantly supporting the market. Moreover, key players are providing strong customer service and technical support, which is creating a positive market outlook.
Agilent Technologies Inc.
Apogee Flow Systems Ltd.
BD (Becton, Dickinson and Company)
Beckman Coulter Inc. (Danaher Corporation)
Bio-RAD Laboratories Inc.
Enzo Life Sciences Inc.
Luminex Corporation
Merck KGaA
Sony Biotechnology Inc.
Sysmex Partec GmbH
Thermo Fisher Scientific Inc.
In February 2023, Agilent Technologies Inc. announced the availability of new NovoExpress software, which brings integrated compliance tools for NovoCyte flow cytometer devices.
In June 2023, BD (Becton, Dickinson and Company) announced the global commercial launch of a new automated device that cleans samples for clinical diagnostics using flow cytometry, offering a full "walkaway" workflow solution intended to increase standardisation and repeatability in cellular diagnostics.
In June 2021, Bio-RAD Laboratories Inc. released three StarBright Dyes made for use in flow cytometry. StarBright Violet 570, 670, and 710 Dyes are appropriate for use in multicolor flow cytometry panels because to their enhanced brightness and accurate excitation and emission spectra.